Dual CAR T cells selectively target HER2-expressing tumor cells with HLA loss of heterozygosity
Weist RM, et al. Poster presentation at the Annual Meeting of the American Association for Cancer Research (AACR). April 2022
Incorporation of inhibitory domains into chimeric antigen receptors designed to reduce on-target-off-tumor toxicity in solid tumor treatment
Bassan D, et al. Poster presentation at the Annual Meeting of the American Association for Cancer Research (AACR). April 2022
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
— Series B financing led by venBio Partners along with co-leads Foresite Capital and Decheng Capital — — New board chair Sheila Gujrathi, M.D., and new president and CEO Sumant Ramachandra, M.D., Ph.D., M.B.A., will drive ImmPACT Bio’s rapid trajectory to advance next-generation CAR T-cell therapies — — Data from Phase 1 clinical study evaluating company’s CD19-CD20 bi-specific CAR […]
ImmPACT Bio Announces Completion of Merger with Kalthera to Progress Next-Generation CAR T Therapies for the Treatment of Cancer
– Enhances ImmPACT Bio’s pipeline with promising clinical candidates including bispecific CAR T-cell therapy candidate in B-cell lymphoma – CAMARILLO, Calif., July 22, 2021 /PRNewswire/ — ImmPACT Bio USA, Inc., a company developing novel cell therapies for treating cancer, today announced its merger with Kalthera, Inc., a biotechnology company. Kalthera is currently progressing a clinical trial at the University of […]
ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing
Company is creating innovative cellular therapeutics for solid tumors CAMARILLO, Calif., Aug. 18, 2020 /PRNewswire/ — ImmPACT Bio USA Inc., a company founded in the FutuRx incubator located in Ness Ziona, Israel, developing novel cell therapies for treating cancer, today announced the closing of a US$ 18 million equity financing round. The financing included OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda […]
